קנדה - אנגלית - Health Canada

mylan pharmaceuticals ulc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium) - tablet - 5mg; 10mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

mylan pharmaceuticals ulc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium) - tablet - 5mg; 20mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

mylan pharmaceuticals ulc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium) - tablet - 5mg; 40mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

apotex inc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium propylene glycol solvate) - tablet - 5mg; 10mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium propylene glycol solvate) 10mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

apotex inc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium propylene glycol solvate) - tablet - 5mg; 20mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium propylene glycol solvate) 20mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

apotex inc - amlodipine (amlodipine besylate); atorvastatin (atorvastatin calcium propylene glycol solvate) - tablet - 5mg; 40mg - amlodipine (amlodipine besylate) 5mg; atorvastatin (atorvastatin calcium propylene glycol solvate) 40mg - hmg-coa reductase inhibitors

ארצות הברית - אנגלית - NLM (National Library of Medicine)

physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - amlodipine 10 mg - amlodipine besylate/atorvastatin calcium tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. and therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, the atorvastatin component of amlodipine besylate/atorvastatin calcium tablets can be started simultaneously with diet restriction. - reduce the risk of myocardial infarction - reduce the risk of stroke - reduce the risk for revascularization procedures and angina - reduce the risk of myocardial infarction - reduce the risk of stroke; - reduce the risk of non-fatal myocardial infarction - reduce the risk of fatal

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 43.4 mg (equivalent: atorvastatin, qty 40 mg); amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; calcium carbonate; microcrystalline cellulose; croscarmellose sodium; hyprolose; magnesium stearate; pregelatinised maize starch; polysorbate 80; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 21.7 mg (equivalent: atorvastatin, qty 20 mg); amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: polysorbate 80; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; calcium carbonate; magnesium stearate; hyprolose; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 10.85 mg (equivalent: atorvastatin, qty 10 mg); amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; calcium carbonate; magnesium stearate; pregelatinised maize starch; polysorbate 80; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.